Coca-Cola sales beat estimates, helped by higher prices

Coca-Cola sales beat estimates, helped by higher prices


Bottles of Coca-Cola are displayed in San Anselmo, California, on April 24, 2023.

Justin Sullivan | Getty Images

Coca-Cola on Tuesday posted quarterly earnings that met expectations and sales that topped estimates, as higher pries helped the beverage maker overcome a volume decline in North America.

Here’s what the company reported compared with what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv:

  • Earnings per share: 49 cents adjusted vs. 49 cents expected
  • Revenue: $10.85 billion vs. $10.68 billion expected

Shares of the company rose less than 1% in premarket trading.



Source

E.l.f. Beauty posts earnings beat, raises full-year guidance
Business

E.l.f. Beauty posts earnings beat, raises full-year guidance

Elf Beauty cosmetics Courtesy: e.l.f Beauty E.l.f. Beauty reported a huge earnings beat Wednesday and raised its guidance for the fiscal year. E.l.f. stock was up as much as 15% in after-hours trading before losing the majority of those gains. Here’s what the company reported for the third fiscal quarter, compared with analyst estimates from […]

Read More
Terrell Owens calls Hall of Fame process ‘broken’ after Belichick, Kraft snubs
Business

Terrell Owens calls Hall of Fame process ‘broken’ after Belichick, Kraft snubs

NFL Hall of Famer Terrell Owens said Wednesday that the recent snubs of New England Patriots owner Robert Kraft and former coach Bill Belichick from the institution show the system is flawed, and someone needs to be held accountable. “It’s just plain dumb” Owens told CNBC Sport in an interview in San Francisco ahead of […]

Read More
Eli Lilly’s GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
Business

Eli Lilly’s GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026

The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters It’s a tale of two drugmakers in the red-hot obesity drug market.  Both Novo Nordisk and Eli Lilly are grappling with lower prices in the U.S., but their 2026 outlooks are diverging sharply: While Novo is bracing for a sales decline, […]

Read More